Optimal use of peritoneal dialysis in patients with diabetes

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Chung, Sung Hee ^a   Noh, Hyunjin ^b   Ha, Hunjoo ^c   Lee, Hi Bahl ^d  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Ewha Womans University   (South Korea)

^d Kim's Clinic and Dialysis Unit   (South Korea)

Author keywords

Congestive heart failure; Diabetes mellitus; End stage renal disease; Infection; Peritoneal membrane; Residual renal function

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PERITONEAL DIALYSIS FLUID; VALSARTAN;

AGING; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; GLOMERULUS FILTRATION RATE; HEALTH; PHYSIOLOGY; REVIEW; STANDARD;

DIABETES MELLITUS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 67449104177     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902902s26     Document Type: Conference Paper

References (9)

1. Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008; 51(Suppl 1):S1-320.
2. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl 2006; (103):S3-11.
3. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT, on behalf of the Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003; 14: 2851-60.
4. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556-64.
5. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT on behalf of the NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046-53.
6. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056-64.
7. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25:38-47.
8. Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006; 69:2022-8.
9. Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 2004; 20:31-6.